Company: DAWN
Filing Date: 2025-12-04
Form Type: SC TO-C
Source: 0001104659-25-118456
Chunk: 2

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-12-04
Form: SC TO-C
Chunk 2
---
 (once they become available) will be mailed to the stockholders of Mersana
free of charge. The information contained in, or that can be accessed through, Day One’s website is not a part of, or incorporated
by reference in, this filing. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well
as the Solicitation/Recommendation Statement, will also be made available for free on the SEC’s website at www.sec.gov. In addition
to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation
Statement, Day One and Mersana file annual, quarterly and current reports, proxy statements and other information with the SEC. You may
read any reports, statements or other information filed by Mersana and Day One with the SEC for free on the SEC’s website at www.sec.gov.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains
forward-looking statements. Forward-looking statements are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans”, “will”, “goal” and
similar expressions. These forward-looking statements include, without limitation, statements related to the anticipated consummation
of the acquisition of Mersana and the expected benefits therefrom; and other statements that are not historical facts. These forward-looking
statements are based on Day One’s current expectations and inherently involve significant risks and uncertainties. Actual results
and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks
and uncertainties, which include, without limitation, risks related to Day One’s ability to complete the transaction on the proposed
terms and schedule, or at all; whether the various conditions to the consummation of the transaction under the Merger Agreement will be
satisfied or waived; whether stockholders of Mersana tender sufficient shares in the transaction; the occurrence of any event, change
or other circumstance that could give rise to the termination of the Merger Agreement; the outcome of legal proceedings that may be instituted
against Day One, Mersana and/or others relating to the transaction and the risk that such legal proceedings may result in significant
costs of defense, indemnification and liability; the failure (or delay) to receive the required regulatory approvals relating to the transaction;
the possibility that competing offers will be made;